Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the
incretin effect during the postprandial period and the subsequent observation that GLP-1 …

Metabolic diseases and diabetes represent an increasing global challenge for human health
care. As associated with a strongly elevated risk of developing atherosclerosis, kidney …

Background: The existence of aberrant myocardial activity and function in the exclusion of
those other cardiovascular events, such as atherosclerosis, hypertension, and severe valve …

Despite the availability of different treatments for type 2 diabetes (T2D), post-diagnosis
complications remain prevalent; therefore, more effective treatments are desired. Glucagon …

In healthy humans, the complex biochemical interplay between organs maintains metabolic
homeostasis and pathological alterations in this process result in impaired metabolic …

Inflammation plays a pathophysiological role in atherosclerosis and its clinical
consequences. In addition to glycemic control, glucagon-like peptide-1 receptor agonists …

A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like
peptide-1, and glucose-dependent insulinotropic polypeptides are released from the …

Heart failure (HF) stands as a formidable challenge in global healthcare casting a long
shadow over both morbidity and mortality. A significant interplay between HF and type 2 …

Prevention of cardiovascular events and regression of atherosclerotic changes are the
primary aims of preventive cardiovascular medicine. Arterial thrombosis is caused by …